[
  {
    "sentence": "Figure 1 presents the PRISMA flow diagram for the clinical literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1: PRISMA Flow Diagram—Clinical Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 presents the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram for the economic literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2: PRISMA Flow Diagram—Economic Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "ONE-WAY SENSITIVITY ANALYSES\nSupplemental Screening With Handheld Ultrasound as an Adjunct to Mammography For supplemental screening with handheld ultrasound for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone and the sensitivity of supplemental screening with ultrasound (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 3: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With Handheld Ultrasound for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Supplemental Screening With MRI as an Adjunct to Mammography\nFor supplemental screening with MRI for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone or of supplemental screening with MRI, the cost of MRI screening and the RR of breast cancer (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Figure 4: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With MRI for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the relative risk of breast cancer for people with heterogeneously dense breasts compared to people with scattered areas of fibroglandular density. (B) For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI and an increase in the sensitivity of mammography alone. and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the RR of breast cancer for people with heterogeneously dense breasts (i.e., 1.51 and 1.75 for the lower and upper bound of the 95% CI, respectively, vs. 1.62 for the reference case) and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI (i.e., 88% for the lower bound of the 95% CI vs. 95% for the reference case), and an increase in the sensitivity of mammography alone (i.e., 70% for the upper bound of the 95% CI vs. 61% for the reference case; Figure 4B).Supplemental Screening With DBT as an Adjunct to Mammography\nFor supplemental screening with DBT for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone, the RR of breast cancer, and the sensitivity of supplemental screening with DBT (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 5: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With DBT for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 6 presents the budget impact model schematic.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 6: Schematic Model of Budget Impact.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 7 presents the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram for the qualitative literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7: PRISMA Flow Diagram—Qualitative Evidence Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "However, previous studies have cited that the Norwegian Ministry of Health and Care Services compare estimated ICERs to a value of 275,000 NOK ($33,805 USD) to 500,000 NOK ($61,464 USD)123–125\n\n\n\nLee et al, 2015,121 United States\nHeterogeneously and extremely dense breasts\nCUA and CEA: cost-effectiveICER $53,893 USD/QALY for biennial mammography supplemented by DBT compared to mammography aloneCommonly accepted cost-effectiveness value: $100,000 USD/QALY\n\n\n\nOpen in a new tab\nAbbreviations: ABUS, automated breast ultrasound; CEA, cost-effectiveness analysis; CUA, cost-utility analysis; DBT, digital breast tomosynthesis; ICER, incremental cost-effectiveness ratio; MRI, magnetic resonance imaging; NICE, National for Health and Care Excellence; QALY, quality-adjusted life-year; NOK, Norwegian kroner.Appendix 9: Model Input Parameters Prepopulated in the OncoSim-Breast Model\nTable A17:\nInputs for Demographic Characteristics, Natural History of Breast Cancer, Detection, and Disease Progression Used in the OncoSim-Breast Model\n\n\nModel parameter\n\nValue\nSource\n\n\n\nDemographic characteristics\nAge distribution of women in Ontario\nPrepopulated in the OncoSim model\nStatistics Canada population and demography statistics136\n\n\n\n\nAll-cause mortality\nPrepopulated in the OncoSim model\nCanadian life tables288\n\n\n\n\nScreening participation and retention rate\n64.81% (screened through the OBSP)\nCSQI 2020 Ontario Cancer System Performance report139\n\n\n\nNatural history of breast cancera\n\nOccult tumour onset (oncogenesis)\nOncogenesis rateb = baseline (age, year) × RR predisposition × RR HRT × RRdensity + AR previous\nYong et al, 2022136 Supplemental Appendix 2: Natural History\n\n\n\nIncidence of tumour type by age groupc\n\n\nDCIS0–54 y: 19%55–64 y: 10%65–69 y: 16%70–79 y: 11%80+ y: 2%Invasive cancer0–54 y: 81%55–64 y: 90%65–69 y: 84%70–79 y: 89%80+ y: 98%\nYong et al, 2022136 Supplemental Appendix 2: Natural History Table 2\n\n\n\n\nTumour growth\nGompertz distribution described byd d(t) = d0([dmax/d0](1-exp[αt]))\nYong et al, 2022136 Supplemental Appendix 2: Natural History Figure 2 and Table 5 (equation coefficients)\n\n\n\nTumour spread\n\nSpread to lymph nodes Number of positive nodes affected is estimated by the size and growth rate of the tumour, years since tumour onset described bye:λ(t)=μN(b1 + b2V[t] + b3V′[t])\nYong et al, 2022136 Supplemental Appendix 2: Natural History; equation developed from the CISNET-Wisconsin model161,289\n\n\n\n\n\n\nMetastasis\nSpread beyond the breast depends on the tumour size and number of positive nodes (N*) described byf:hazard of metastasis = μM* k(tumour size, N*)\nYong et al, 2022 136 Supplemental Appendix 2: Natural History\n\n\nCancer detection, staging, and tumour biologya\n\nProbability of clinical detection of tumour\nDetermined by tumour size\nYong et al, 2022136 Supplemental Appendix 3: Cancer detection, staging and tumour biology Table 7\n\n\n\n\nStage at detectiong\n\nAssigned based on tumour size (T), nodal status (N) and metastasis (M)\nAmerican Joint Committee on Cancer (AJCC) version 7 classification290\n\n\n\n\nTumour biology: hormone receptor status, HER2 status and grade\nEstimated by tumour size, nodal involvement, metastatic status, and age of woman at tumour detection\nCanadian Cancer Registry140\n\n\n\nDisease progression\nTime to disease progression\nEstimated using Weibull regression models, adjusted to years since diagnosis, age, grade, hormone status, HER2 status, screening status, method of detection, and variable interactions\nYong et al, 2022136 Supplemental Appendix 5: Disease Progression Figure 6\n\n\n\n\nOpen in a new tab\n\nAbbreviations: AR, adjusted risk; CISNET, Cancer Intervention and Surveillance Modeling Network; CSQI, Cancer System Quality Index; DCIS, ductal carcinoma in situ; HER2, human epidermal growth factor receptor 2; HRT, hormone replacement therapy; OBSP, Ontario Breast Screening Program; RR, relative risk; Wisconsin model, University of Wisconsin Breast Cancer Epidemiology Simulation Model.\n\naThe natural history of breast cancer component of the OncoSim model and corresponding inputs (including tumour onset, growth, spread and metastasis, and clinical detection) were adapted from the Wisconsin model289 and calibrated to the incidence of cancer by age group and year in the National Cancer Incidence Reporting System (1969–1991), the Canadian Cancer Registry (1992–2013) and the Canadian Breast Cancer Screening Database (2007–2008).\n\n\nbOncogenesis rate or tumour onset is calculated by the baseline term, which is the assumed hazard of developing an occult tumour based on age and year for all simulated women, multiplied by the increased risk of breast cancer due to high breast density (RRdensity, women with dense breasts vs. without dense breasts).\n\n\ncOnce a tumour is simulated (oncogenesis), the model determines the tumour type (DCIS or invasive) using incidence of tumour type by age group.\n\n\ndTumours are assumed to grow according to a Gompertz distribution that estimates the tumour diameter (d, in cm) as a function of years since tumour onset (t), scaled to the maximum diameter allowed for a particular tumour type (dmax), where d0 is the diameter of the tumour at occult onset (0.2 cm) and a represents the tumour growth rate (model fitting).\n\n\neInvasive tumour can spread into the lymph nodes in which the spread (number of positive nodes, λ) is estimated by the size and growth rate of the tumour and years since tumour onset (t), where μN is the random term drawn at time of tumour onset that allows for heterogeneity of tumours to generate positive nodes (Yong et al,136 Supplemental Appendix 2, Natural History Table 6); b1, b2, and b3 are coefficients estimated through calibration of natural history; V(t) is the volume of the spherical tumour; and V'(t) represents the growth rate of the volume, and is the derivative of V(t).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 1 presents the PRISMA flow diagram for the clinical literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1: PRISMA Flow Diagram—Clinical Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 presents the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram for the economic literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2: PRISMA Flow Diagram—Economic Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "ONE-WAY SENSITIVITY ANALYSES\nSupplemental Screening With Handheld Ultrasound as an Adjunct to Mammography For supplemental screening with handheld ultrasound for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone and the sensitivity of supplemental screening with ultrasound (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 3: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With Handheld Ultrasound for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Supplemental Screening With MRI as an Adjunct to Mammography\nFor supplemental screening with MRI for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone or of supplemental screening with MRI, the cost of MRI screening and the RR of breast cancer (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Figure 4: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With MRI for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the relative risk of breast cancer for people with heterogeneously dense breasts compared to people with scattered areas of fibroglandular density. (B) For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI and an increase in the sensitivity of mammography alone. and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the RR of breast cancer for people with heterogeneously dense breasts (i.e., 1.51 and 1.75 for the lower and upper bound of the 95% CI, respectively, vs. 1.62 for the reference case) and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI (i.e., 88% for the lower bound of the 95% CI vs. 95% for the reference case), and an increase in the sensitivity of mammography alone (i.e., 70% for the upper bound of the 95% CI vs. 61% for the reference case; Figure 4B).Supplemental Screening With DBT as an Adjunct to Mammography\nFor supplemental screening with DBT for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone, the RR of breast cancer, and the sensitivity of supplemental screening with DBT (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 5: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With DBT for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 6 presents the budget impact model schematic.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 6: Schematic Model of Budget Impact.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 7 presents the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram for the qualitative literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7: PRISMA Flow Diagram—Qualitative Evidence Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "However, previous studies have cited that the Norwegian Ministry of Health and Care Services compare estimated ICERs to a value of 275,000 NOK ($33,805 USD) to 500,000 NOK ($61,464 USD)123–125\n\n\n\nLee et al, 2015,121 United States\nHeterogeneously and extremely dense breasts\nCUA and CEA: cost-effectiveICER $53,893 USD/QALY for biennial mammography supplemented by DBT compared to mammography aloneCommonly accepted cost-effectiveness value: $100,000 USD/QALY\n\n\n\nOpen in a new tab\nAbbreviations: ABUS, automated breast ultrasound; CEA, cost-effectiveness analysis; CUA, cost-utility analysis; DBT, digital breast tomosynthesis; ICER, incremental cost-effectiveness ratio; MRI, magnetic resonance imaging; NICE, National for Health and Care Excellence; QALY, quality-adjusted life-year; NOK, Norwegian kroner.Appendix 9: Model Input Parameters Prepopulated in the OncoSim-Breast Model\nTable A17:\nInputs for Demographic Characteristics, Natural History of Breast Cancer, Detection, and Disease Progression Used in the OncoSim-Breast Model\n\n\nModel parameter\n\nValue\nSource\n\n\n\nDemographic characteristics\nAge distribution of women in Ontario\nPrepopulated in the OncoSim model\nStatistics Canada population and demography statistics136\n\n\n\n\nAll-cause mortality\nPrepopulated in the OncoSim model\nCanadian life tables288\n\n\n\n\nScreening participation and retention rate\n64.81% (screened through the OBSP)\nCSQI 2020 Ontario Cancer System Performance report139\n\n\n\nNatural history of breast cancera\n\nOccult tumour onset (oncogenesis)\nOncogenesis rateb = baseline (age, year) × RR predisposition × RR HRT × RRdensity + AR previous\nYong et al, 2022136 Supplemental Appendix 2: Natural History\n\n\n\nIncidence of tumour type by age groupc\n\n\nDCIS0–54 y: 19%55–64 y: 10%65–69 y: 16%70–79 y: 11%80+ y: 2%Invasive cancer0–54 y: 81%55–64 y: 90%65–69 y: 84%70–79 y: 89%80+ y: 98%\nYong et al, 2022136 Supplemental Appendix 2: Natural History Table 2\n\n\n\n\nTumour growth\nGompertz distribution described byd d(t) = d0([dmax/d0](1-exp[αt]))\nYong et al, 2022136 Supplemental Appendix 2: Natural History Figure 2 and Table 5 (equation coefficients)\n\n\n\nTumour spread\n\nSpread to lymph nodes Number of positive nodes affected is estimated by the size and growth rate of the tumour, years since tumour onset described bye:λ(t)=μN(b1 + b2V[t] + b3V′[t])\nYong et al, 2022136 Supplemental Appendix 2: Natural History; equation developed from the CISNET-Wisconsin model161,289\n\n\n\n\n\n\nMetastasis\nSpread beyond the breast depends on the tumour size and number of positive nodes (N*) described byf:hazard of metastasis = μM* k(tumour size, N*)\nYong et al, 2022 136 Supplemental Appendix 2: Natural History\n\n\nCancer detection, staging, and tumour biologya\n\nProbability of clinical detection of tumour\nDetermined by tumour size\nYong et al, 2022136 Supplemental Appendix 3: Cancer detection, staging and tumour biology Table 7\n\n\n\n\nStage at detectiong\n\nAssigned based on tumour size (T), nodal status (N) and metastasis (M)\nAmerican Joint Committee on Cancer (AJCC) version 7 classification290\n\n\n\n\nTumour biology: hormone receptor status, HER2 status and grade\nEstimated by tumour size, nodal involvement, metastatic status, and age of woman at tumour detection\nCanadian Cancer Registry140\n\n\n\nDisease progression\nTime to disease progression\nEstimated using Weibull regression models, adjusted to years since diagnosis, age, grade, hormone status, HER2 status, screening status, method of detection, and variable interactions\nYong et al, 2022136 Supplemental Appendix 5: Disease Progression Figure 6\n\n\n\n\nOpen in a new tab\n\nAbbreviations: AR, adjusted risk; CISNET, Cancer Intervention and Surveillance Modeling Network; CSQI, Cancer System Quality Index; DCIS, ductal carcinoma in situ; HER2, human epidermal growth factor receptor 2; HRT, hormone replacement therapy; OBSP, Ontario Breast Screening Program; RR, relative risk; Wisconsin model, University of Wisconsin Breast Cancer Epidemiology Simulation Model.\n\naThe natural history of breast cancer component of the OncoSim model and corresponding inputs (including tumour onset, growth, spread and metastasis, and clinical detection) were adapted from the Wisconsin model289 and calibrated to the incidence of cancer by age group and year in the National Cancer Incidence Reporting System (1969–1991), the Canadian Cancer Registry (1992–2013) and the Canadian Breast Cancer Screening Database (2007–2008).\n\n\nbOncogenesis rate or tumour onset is calculated by the baseline term, which is the assumed hazard of developing an occult tumour based on age and year for all simulated women, multiplied by the increased risk of breast cancer due to high breast density (RRdensity, women with dense breasts vs. without dense breasts).\n\n\ncOnce a tumour is simulated (oncogenesis), the model determines the tumour type (DCIS or invasive) using incidence of tumour type by age group.\n\n\ndTumours are assumed to grow according to a Gompertz distribution that estimates the tumour diameter (d, in cm) as a function of years since tumour onset (t), scaled to the maximum diameter allowed for a particular tumour type (dmax), where d0 is the diameter of the tumour at occult onset (0.2 cm) and a represents the tumour growth rate (model fitting).\n\n\neInvasive tumour can spread into the lymph nodes in which the spread (number of positive nodes, λ) is estimated by the size and growth rate of the tumour and years since tumour onset (t), where μN is the random term drawn at time of tumour onset that allows for heterogeneity of tumours to generate positive nodes (Yong et al,136 Supplemental Appendix 2, Natural History Table 6); b1, b2, and b3 are coefficients estimated through calibration of natural history; V(t) is the volume of the spherical tumour; and V'(t) represents the growth rate of the volume, and is the derivative of V(t).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 1 presents the PRISMA flow diagram for the clinical literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1: PRISMA Flow Diagram—Clinical Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 presents the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram for the economic literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2: PRISMA Flow Diagram—Economic Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "ONE-WAY SENSITIVITY ANALYSES\nSupplemental Screening With Handheld Ultrasound as an Adjunct to Mammography For supplemental screening with handheld ultrasound for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone and the sensitivity of supplemental screening with ultrasound (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 3: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With Handheld Ultrasound for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Supplemental Screening With MRI as an Adjunct to Mammography\nFor supplemental screening with MRI for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone or of supplemental screening with MRI, the cost of MRI screening and the RR of breast cancer (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Figure 4: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With MRI for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the relative risk of breast cancer for people with heterogeneously dense breasts compared to people with scattered areas of fibroglandular density. (B) For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI and an increase in the sensitivity of mammography alone. and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the RR of breast cancer for people with heterogeneously dense breasts (i.e., 1.51 and 1.75 for the lower and upper bound of the 95% CI, respectively, vs. 1.62 for the reference case) and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI (i.e., 88% for the lower bound of the 95% CI vs. 95% for the reference case), and an increase in the sensitivity of mammography alone (i.e., 70% for the upper bound of the 95% CI vs. 61% for the reference case; Figure 4B).Supplemental Screening With DBT as an Adjunct to Mammography\nFor supplemental screening with DBT for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone, the RR of breast cancer, and the sensitivity of supplemental screening with DBT (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 5: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With DBT for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 6 presents the budget impact model schematic.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 6: Schematic Model of Budget Impact.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 7 presents the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram for the qualitative literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7: PRISMA Flow Diagram—Qualitative Evidence Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "However, previous studies have cited that the Norwegian Ministry of Health and Care Services compare estimated ICERs to a value of 275,000 NOK ($33,805 USD) to 500,000 NOK ($61,464 USD)123–125\n\n\n\nLee et al, 2015,121 United States\nHeterogeneously and extremely dense breasts\nCUA and CEA: cost-effectiveICER $53,893 USD/QALY for biennial mammography supplemented by DBT compared to mammography aloneCommonly accepted cost-effectiveness value: $100,000 USD/QALY\n\n\n\nOpen in a new tab\nAbbreviations: ABUS, automated breast ultrasound; CEA, cost-effectiveness analysis; CUA, cost-utility analysis; DBT, digital breast tomosynthesis; ICER, incremental cost-effectiveness ratio; MRI, magnetic resonance imaging; NICE, National for Health and Care Excellence; QALY, quality-adjusted life-year; NOK, Norwegian kroner.Appendix 9: Model Input Parameters Prepopulated in the OncoSim-Breast Model\nTable A17:\nInputs for Demographic Characteristics, Natural History of Breast Cancer, Detection, and Disease Progression Used in the OncoSim-Breast Model\n\n\nModel parameter\n\nValue\nSource\n\n\n\nDemographic characteristics\nAge distribution of women in Ontario\nPrepopulated in the OncoSim model\nStatistics Canada population and demography statistics136\n\n\n\n\nAll-cause mortality\nPrepopulated in the OncoSim model\nCanadian life tables288\n\n\n\n\nScreening participation and retention rate\n64.81% (screened through the OBSP)\nCSQI 2020 Ontario Cancer System Performance report139\n\n\n\nNatural history of breast cancera\n\nOccult tumour onset (oncogenesis)\nOncogenesis rateb = baseline (age, year) × RR predisposition × RR HRT × RRdensity + AR previous\nYong et al, 2022136 Supplemental Appendix 2: Natural History\n\n\n\nIncidence of tumour type by age groupc\n\n\nDCIS0–54 y: 19%55–64 y: 10%65–69 y: 16%70–79 y: 11%80+ y: 2%Invasive cancer0–54 y: 81%55–64 y: 90%65–69 y: 84%70–79 y: 89%80+ y: 98%\nYong et al, 2022136 Supplemental Appendix 2: Natural History Table 2\n\n\n\n\nTumour growth\nGompertz distribution described byd d(t) = d0([dmax/d0](1-exp[αt]))\nYong et al, 2022136 Supplemental Appendix 2: Natural History Figure 2 and Table 5 (equation coefficients)\n\n\n\nTumour spread\n\nSpread to lymph nodes Number of positive nodes affected is estimated by the size and growth rate of the tumour, years since tumour onset described bye:λ(t)=μN(b1 + b2V[t] + b3V′[t])\nYong et al, 2022136 Supplemental Appendix 2: Natural History; equation developed from the CISNET-Wisconsin model161,289\n\n\n\n\n\n\nMetastasis\nSpread beyond the breast depends on the tumour size and number of positive nodes (N*) described byf:hazard of metastasis = μM* k(tumour size, N*)\nYong et al, 2022 136 Supplemental Appendix 2: Natural History\n\n\nCancer detection, staging, and tumour biologya\n\nProbability of clinical detection of tumour\nDetermined by tumour size\nYong et al, 2022136 Supplemental Appendix 3: Cancer detection, staging and tumour biology Table 7\n\n\n\n\nStage at detectiong\n\nAssigned based on tumour size (T), nodal status (N) and metastasis (M)\nAmerican Joint Committee on Cancer (AJCC) version 7 classification290\n\n\n\n\nTumour biology: hormone receptor status, HER2 status and grade\nEstimated by tumour size, nodal involvement, metastatic status, and age of woman at tumour detection\nCanadian Cancer Registry140\n\n\n\nDisease progression\nTime to disease progression\nEstimated using Weibull regression models, adjusted to years since diagnosis, age, grade, hormone status, HER2 status, screening status, method of detection, and variable interactions\nYong et al, 2022136 Supplemental Appendix 5: Disease Progression Figure 6\n\n\n\n\nOpen in a new tab\n\nAbbreviations: AR, adjusted risk; CISNET, Cancer Intervention and Surveillance Modeling Network; CSQI, Cancer System Quality Index; DCIS, ductal carcinoma in situ; HER2, human epidermal growth factor receptor 2; HRT, hormone replacement therapy; OBSP, Ontario Breast Screening Program; RR, relative risk; Wisconsin model, University of Wisconsin Breast Cancer Epidemiology Simulation Model.\n\naThe natural history of breast cancer component of the OncoSim model and corresponding inputs (including tumour onset, growth, spread and metastasis, and clinical detection) were adapted from the Wisconsin model289 and calibrated to the incidence of cancer by age group and year in the National Cancer Incidence Reporting System (1969–1991), the Canadian Cancer Registry (1992–2013) and the Canadian Breast Cancer Screening Database (2007–2008).\n\n\nbOncogenesis rate or tumour onset is calculated by the baseline term, which is the assumed hazard of developing an occult tumour based on age and year for all simulated women, multiplied by the increased risk of breast cancer due to high breast density (RRdensity, women with dense breasts vs. without dense breasts).\n\n\ncOnce a tumour is simulated (oncogenesis), the model determines the tumour type (DCIS or invasive) using incidence of tumour type by age group.\n\n\ndTumours are assumed to grow according to a Gompertz distribution that estimates the tumour diameter (d, in cm) as a function of years since tumour onset (t), scaled to the maximum diameter allowed for a particular tumour type (dmax), where d0 is the diameter of the tumour at occult onset (0.2 cm) and a represents the tumour growth rate (model fitting).\n\n\neInvasive tumour can spread into the lymph nodes in which the spread (number of positive nodes, λ) is estimated by the size and growth rate of the tumour and years since tumour onset (t), where μN is the random term drawn at time of tumour onset that allows for heterogeneity of tumours to generate positive nodes (Yong et al,136 Supplemental Appendix 2, Natural History Table 6); b1, b2, and b3 are coefficients estimated through calibration of natural history; V(t) is the volume of the spherical tumour; and V'(t) represents the growth rate of the volume, and is the derivative of V(t).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 1 presents the PRISMA flow diagram for the clinical literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1: PRISMA Flow Diagram—Clinical Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 presents the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram for the economic literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2: PRISMA Flow Diagram—Economic Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "ONE-WAY SENSITIVITY ANALYSES\nSupplemental Screening With Handheld Ultrasound as an Adjunct to Mammography For supplemental screening with handheld ultrasound for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone and the sensitivity of supplemental screening with ultrasound (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 3: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With Handheld Ultrasound for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Supplemental Screening With MRI as an Adjunct to Mammography\nFor supplemental screening with MRI for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone or of supplemental screening with MRI, the cost of MRI screening and the RR of breast cancer (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Figure 4: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With MRI for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the relative risk of breast cancer for people with heterogeneously dense breasts compared to people with scattered areas of fibroglandular density. (B) For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI and an increase in the sensitivity of mammography alone. and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the RR of breast cancer for people with heterogeneously dense breasts (i.e., 1.51 and 1.75 for the lower and upper bound of the 95% CI, respectively, vs. 1.62 for the reference case) and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI (i.e., 88% for the lower bound of the 95% CI vs. 95% for the reference case), and an increase in the sensitivity of mammography alone (i.e., 70% for the upper bound of the 95% CI vs. 61% for the reference case; Figure 4B).Supplemental Screening With DBT as an Adjunct to Mammography\nFor supplemental screening with DBT for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone, the RR of breast cancer, and the sensitivity of supplemental screening with DBT (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 5: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With DBT for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 6 presents the budget impact model schematic.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 6: Schematic Model of Budget Impact.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 7 presents the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram for the qualitative literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7: PRISMA Flow Diagram—Qualitative Evidence Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "However, previous studies have cited that the Norwegian Ministry of Health and Care Services compare estimated ICERs to a value of 275,000 NOK ($33,805 USD) to 500,000 NOK ($61,464 USD)123–125\n\n\n\nLee et al, 2015,121 United States\nHeterogeneously and extremely dense breasts\nCUA and CEA: cost-effectiveICER $53,893 USD/QALY for biennial mammography supplemented by DBT compared to mammography aloneCommonly accepted cost-effectiveness value: $100,000 USD/QALY\n\n\n\nOpen in a new tab\nAbbreviations: ABUS, automated breast ultrasound; CEA, cost-effectiveness analysis; CUA, cost-utility analysis; DBT, digital breast tomosynthesis; ICER, incremental cost-effectiveness ratio; MRI, magnetic resonance imaging; NICE, National for Health and Care Excellence; QALY, quality-adjusted life-year; NOK, Norwegian kroner.Appendix 9: Model Input Parameters Prepopulated in the OncoSim-Breast Model\nTable A17:\nInputs for Demographic Characteristics, Natural History of Breast Cancer, Detection, and Disease Progression Used in the OncoSim-Breast Model\n\n\nModel parameter\n\nValue\nSource\n\n\n\nDemographic characteristics\nAge distribution of women in Ontario\nPrepopulated in the OncoSim model\nStatistics Canada population and demography statistics136\n\n\n\n\nAll-cause mortality\nPrepopulated in the OncoSim model\nCanadian life tables288\n\n\n\n\nScreening participation and retention rate\n64.81% (screened through the OBSP)\nCSQI 2020 Ontario Cancer System Performance report139\n\n\n\nNatural history of breast cancera\n\nOccult tumour onset (oncogenesis)\nOncogenesis rateb = baseline (age, year) × RR predisposition × RR HRT × RRdensity + AR previous\nYong et al, 2022136 Supplemental Appendix 2: Natural History\n\n\n\nIncidence of tumour type by age groupc\n\n\nDCIS0–54 y: 19%55–64 y: 10%65–69 y: 16%70–79 y: 11%80+ y: 2%Invasive cancer0–54 y: 81%55–64 y: 90%65–69 y: 84%70–79 y: 89%80+ y: 98%\nYong et al, 2022136 Supplemental Appendix 2: Natural History Table 2\n\n\n\n\nTumour growth\nGompertz distribution described byd d(t) = d0([dmax/d0](1-exp[αt]))\nYong et al, 2022136 Supplemental Appendix 2: Natural History Figure 2 and Table 5 (equation coefficients)\n\n\n\nTumour spread\n\nSpread to lymph nodes Number of positive nodes affected is estimated by the size and growth rate of the tumour, years since tumour onset described bye:λ(t)=μN(b1 + b2V[t] + b3V′[t])\nYong et al, 2022136 Supplemental Appendix 2: Natural History; equation developed from the CISNET-Wisconsin model161,289\n\n\n\n\n\n\nMetastasis\nSpread beyond the breast depends on the tumour size and number of positive nodes (N*) described byf:hazard of metastasis = μM* k(tumour size, N*)\nYong et al, 2022 136 Supplemental Appendix 2: Natural History\n\n\nCancer detection, staging, and tumour biologya\n\nProbability of clinical detection of tumour\nDetermined by tumour size\nYong et al, 2022136 Supplemental Appendix 3: Cancer detection, staging and tumour biology Table 7\n\n\n\n\nStage at detectiong\n\nAssigned based on tumour size (T), nodal status (N) and metastasis (M)\nAmerican Joint Committee on Cancer (AJCC) version 7 classification290\n\n\n\n\nTumour biology: hormone receptor status, HER2 status and grade\nEstimated by tumour size, nodal involvement, metastatic status, and age of woman at tumour detection\nCanadian Cancer Registry140\n\n\n\nDisease progression\nTime to disease progression\nEstimated using Weibull regression models, adjusted to years since diagnosis, age, grade, hormone status, HER2 status, screening status, method of detection, and variable interactions\nYong et al, 2022136 Supplemental Appendix 5: Disease Progression Figure 6\n\n\n\n\nOpen in a new tab\n\nAbbreviations: AR, adjusted risk; CISNET, Cancer Intervention and Surveillance Modeling Network; CSQI, Cancer System Quality Index; DCIS, ductal carcinoma in situ; HER2, human epidermal growth factor receptor 2; HRT, hormone replacement therapy; OBSP, Ontario Breast Screening Program; RR, relative risk; Wisconsin model, University of Wisconsin Breast Cancer Epidemiology Simulation Model.\n\naThe natural history of breast cancer component of the OncoSim model and corresponding inputs (including tumour onset, growth, spread and metastasis, and clinical detection) were adapted from the Wisconsin model289 and calibrated to the incidence of cancer by age group and year in the National Cancer Incidence Reporting System (1969–1991), the Canadian Cancer Registry (1992–2013) and the Canadian Breast Cancer Screening Database (2007–2008).\n\n\nbOncogenesis rate or tumour onset is calculated by the baseline term, which is the assumed hazard of developing an occult tumour based on age and year for all simulated women, multiplied by the increased risk of breast cancer due to high breast density (RRdensity, women with dense breasts vs. without dense breasts).\n\n\ncOnce a tumour is simulated (oncogenesis), the model determines the tumour type (DCIS or invasive) using incidence of tumour type by age group.\n\n\ndTumours are assumed to grow according to a Gompertz distribution that estimates the tumour diameter (d, in cm) as a function of years since tumour onset (t), scaled to the maximum diameter allowed for a particular tumour type (dmax), where d0 is the diameter of the tumour at occult onset (0.2 cm) and a represents the tumour growth rate (model fitting).\n\n\neInvasive tumour can spread into the lymph nodes in which the spread (number of positive nodes, λ) is estimated by the size and growth rate of the tumour and years since tumour onset (t), where μN is the random term drawn at time of tumour onset that allows for heterogeneity of tumours to generate positive nodes (Yong et al,136 Supplemental Appendix 2, Natural History Table 6); b1, b2, and b3 are coefficients estimated through calibration of natural history; V(t) is the volume of the spherical tumour; and V'(t) represents the growth rate of the volume, and is the derivative of V(t).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 1 presents the PRISMA flow diagram for the clinical literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1: PRISMA Flow Diagram—Clinical Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 presents the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram for the economic literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2: PRISMA Flow Diagram—Economic Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "ONE-WAY SENSITIVITY ANALYSES\nSupplemental Screening With Handheld Ultrasound as an Adjunct to Mammography For supplemental screening with handheld ultrasound for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone and the sensitivity of supplemental screening with ultrasound (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 3: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With Handheld Ultrasound for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Supplemental Screening With MRI as an Adjunct to Mammography\nFor supplemental screening with MRI for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone or of supplemental screening with MRI, the cost of MRI screening and the RR of breast cancer (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Figure 4: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With MRI for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the relative risk of breast cancer for people with heterogeneously dense breasts compared to people with scattered areas of fibroglandular density. (B) For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI and an increase in the sensitivity of mammography alone. and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the RR of breast cancer for people with heterogeneously dense breasts (i.e., 1.51 and 1.75 for the lower and upper bound of the 95% CI, respectively, vs. 1.62 for the reference case) and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI (i.e., 88% for the lower bound of the 95% CI vs. 95% for the reference case), and an increase in the sensitivity of mammography alone (i.e., 70% for the upper bound of the 95% CI vs. 61% for the reference case; Figure 4B).Supplemental Screening With DBT as an Adjunct to Mammography\nFor supplemental screening with DBT for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone, the RR of breast cancer, and the sensitivity of supplemental screening with DBT (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 5: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With DBT for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 6 presents the budget impact model schematic.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 6: Schematic Model of Budget Impact.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 7 presents the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram for the qualitative literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7: PRISMA Flow Diagram—Qualitative Evidence Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "However, previous studies have cited that the Norwegian Ministry of Health and Care Services compare estimated ICERs to a value of 275,000 NOK ($33,805 USD) to 500,000 NOK ($61,464 USD)123–125\n\n\n\nLee et al, 2015,121 United States\nHeterogeneously and extremely dense breasts\nCUA and CEA: cost-effectiveICER $53,893 USD/QALY for biennial mammography supplemented by DBT compared to mammography aloneCommonly accepted cost-effectiveness value: $100,000 USD/QALY\n\n\n\nOpen in a new tab\nAbbreviations: ABUS, automated breast ultrasound; CEA, cost-effectiveness analysis; CUA, cost-utility analysis; DBT, digital breast tomosynthesis; ICER, incremental cost-effectiveness ratio; MRI, magnetic resonance imaging; NICE, National for Health and Care Excellence; QALY, quality-adjusted life-year; NOK, Norwegian kroner.Appendix 9: Model Input Parameters Prepopulated in the OncoSim-Breast Model\nTable A17:\nInputs for Demographic Characteristics, Natural History of Breast Cancer, Detection, and Disease Progression Used in the OncoSim-Breast Model\n\n\nModel parameter\n\nValue\nSource\n\n\n\nDemographic characteristics\nAge distribution of women in Ontario\nPrepopulated in the OncoSim model\nStatistics Canada population and demography statistics136\n\n\n\n\nAll-cause mortality\nPrepopulated in the OncoSim model\nCanadian life tables288\n\n\n\n\nScreening participation and retention rate\n64.81% (screened through the OBSP)\nCSQI 2020 Ontario Cancer System Performance report139\n\n\n\nNatural history of breast cancera\n\nOccult tumour onset (oncogenesis)\nOncogenesis rateb = baseline (age, year) × RR predisposition × RR HRT × RRdensity + AR previous\nYong et al, 2022136 Supplemental Appendix 2: Natural History\n\n\n\nIncidence of tumour type by age groupc\n\n\nDCIS0–54 y: 19%55–64 y: 10%65–69 y: 16%70–79 y: 11%80+ y: 2%Invasive cancer0–54 y: 81%55–64 y: 90%65–69 y: 84%70–79 y: 89%80+ y: 98%\nYong et al, 2022136 Supplemental Appendix 2: Natural History Table 2\n\n\n\n\nTumour growth\nGompertz distribution described byd d(t) = d0([dmax/d0](1-exp[αt]))\nYong et al, 2022136 Supplemental Appendix 2: Natural History Figure 2 and Table 5 (equation coefficients)\n\n\n\nTumour spread\n\nSpread to lymph nodes Number of positive nodes affected is estimated by the size and growth rate of the tumour, years since tumour onset described bye:λ(t)=μN(b1 + b2V[t] + b3V′[t])\nYong et al, 2022136 Supplemental Appendix 2: Natural History; equation developed from the CISNET-Wisconsin model161,289\n\n\n\n\n\n\nMetastasis\nSpread beyond the breast depends on the tumour size and number of positive nodes (N*) described byf:hazard of metastasis = μM* k(tumour size, N*)\nYong et al, 2022 136 Supplemental Appendix 2: Natural History\n\n\nCancer detection, staging, and tumour biologya\n\nProbability of clinical detection of tumour\nDetermined by tumour size\nYong et al, 2022136 Supplemental Appendix 3: Cancer detection, staging and tumour biology Table 7\n\n\n\n\nStage at detectiong\n\nAssigned based on tumour size (T), nodal status (N) and metastasis (M)\nAmerican Joint Committee on Cancer (AJCC) version 7 classification290\n\n\n\n\nTumour biology: hormone receptor status, HER2 status and grade\nEstimated by tumour size, nodal involvement, metastatic status, and age of woman at tumour detection\nCanadian Cancer Registry140\n\n\n\nDisease progression\nTime to disease progression\nEstimated using Weibull regression models, adjusted to years since diagnosis, age, grade, hormone status, HER2 status, screening status, method of detection, and variable interactions\nYong et al, 2022136 Supplemental Appendix 5: Disease Progression Figure 6\n\n\n\n\nOpen in a new tab\n\nAbbreviations: AR, adjusted risk; CISNET, Cancer Intervention and Surveillance Modeling Network; CSQI, Cancer System Quality Index; DCIS, ductal carcinoma in situ; HER2, human epidermal growth factor receptor 2; HRT, hormone replacement therapy; OBSP, Ontario Breast Screening Program; RR, relative risk; Wisconsin model, University of Wisconsin Breast Cancer Epidemiology Simulation Model.\n\naThe natural history of breast cancer component of the OncoSim model and corresponding inputs (including tumour onset, growth, spread and metastasis, and clinical detection) were adapted from the Wisconsin model289 and calibrated to the incidence of cancer by age group and year in the National Cancer Incidence Reporting System (1969–1991), the Canadian Cancer Registry (1992–2013) and the Canadian Breast Cancer Screening Database (2007–2008).\n\n\nbOncogenesis rate or tumour onset is calculated by the baseline term, which is the assumed hazard of developing an occult tumour based on age and year for all simulated women, multiplied by the increased risk of breast cancer due to high breast density (RRdensity, women with dense breasts vs. without dense breasts).\n\n\ncOnce a tumour is simulated (oncogenesis), the model determines the tumour type (DCIS or invasive) using incidence of tumour type by age group.\n\n\ndTumours are assumed to grow according to a Gompertz distribution that estimates the tumour diameter (d, in cm) as a function of years since tumour onset (t), scaled to the maximum diameter allowed for a particular tumour type (dmax), where d0 is the diameter of the tumour at occult onset (0.2 cm) and a represents the tumour growth rate (model fitting).\n\n\neInvasive tumour can spread into the lymph nodes in which the spread (number of positive nodes, λ) is estimated by the size and growth rate of the tumour and years since tumour onset (t), where μN is the random term drawn at time of tumour onset that allows for heterogeneity of tumours to generate positive nodes (Yong et al,136 Supplemental Appendix 2, Natural History Table 6); b1, b2, and b3 are coefficients estimated through calibration of natural history; V(t) is the volume of the spherical tumour; and V'(t) represents the growth rate of the volume, and is the derivative of V(t).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 1 presents the PRISMA flow diagram for the clinical literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1: PRISMA Flow Diagram—Clinical Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 presents the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram for the economic literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2: PRISMA Flow Diagram—Economic Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "ONE-WAY SENSITIVITY ANALYSES\nSupplemental Screening With Handheld Ultrasound as an Adjunct to Mammography For supplemental screening with handheld ultrasound for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone and the sensitivity of supplemental screening with ultrasound (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 3: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With Handheld Ultrasound for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Supplemental Screening With MRI as an Adjunct to Mammography\nFor supplemental screening with MRI for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone or of supplemental screening with MRI, the cost of MRI screening and the RR of breast cancer (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Figure 4: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With MRI for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the relative risk of breast cancer for people with heterogeneously dense breasts compared to people with scattered areas of fibroglandular density. (B) For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI and an increase in the sensitivity of mammography alone. and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the RR of breast cancer for people with heterogeneously dense breasts (i.e., 1.51 and 1.75 for the lower and upper bound of the 95% CI, respectively, vs. 1.62 for the reference case) and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI (i.e., 88% for the lower bound of the 95% CI vs. 95% for the reference case), and an increase in the sensitivity of mammography alone (i.e., 70% for the upper bound of the 95% CI vs. 61% for the reference case; Figure 4B).Supplemental Screening With DBT as an Adjunct to Mammography\nFor supplemental screening with DBT for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone, the RR of breast cancer, and the sensitivity of supplemental screening with DBT (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 5: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With DBT for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 6 presents the budget impact model schematic.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 6: Schematic Model of Budget Impact.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 7 presents the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram for the qualitative literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7: PRISMA Flow Diagram—Qualitative Evidence Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "However, previous studies have cited that the Norwegian Ministry of Health and Care Services compare estimated ICERs to a value of 275,000 NOK ($33,805 USD) to 500,000 NOK ($61,464 USD)123–125\n\n\n\nLee et al, 2015,121 United States\nHeterogeneously and extremely dense breasts\nCUA and CEA: cost-effectiveICER $53,893 USD/QALY for biennial mammography supplemented by DBT compared to mammography aloneCommonly accepted cost-effectiveness value: $100,000 USD/QALY\n\n\n\nOpen in a new tab\nAbbreviations: ABUS, automated breast ultrasound; CEA, cost-effectiveness analysis; CUA, cost-utility analysis; DBT, digital breast tomosynthesis; ICER, incremental cost-effectiveness ratio; MRI, magnetic resonance imaging; NICE, National for Health and Care Excellence; QALY, quality-adjusted life-year; NOK, Norwegian kroner.Appendix 9: Model Input Parameters Prepopulated in the OncoSim-Breast Model\nTable A17:\nInputs for Demographic Characteristics, Natural History of Breast Cancer, Detection, and Disease Progression Used in the OncoSim-Breast Model\n\n\nModel parameter\n\nValue\nSource\n\n\n\nDemographic characteristics\nAge distribution of women in Ontario\nPrepopulated in the OncoSim model\nStatistics Canada population and demography statistics136\n\n\n\n\nAll-cause mortality\nPrepopulated in the OncoSim model\nCanadian life tables288\n\n\n\n\nScreening participation and retention rate\n64.81% (screened through the OBSP)\nCSQI 2020 Ontario Cancer System Performance report139\n\n\n\nNatural history of breast cancera\n\nOccult tumour onset (oncogenesis)\nOncogenesis rateb = baseline (age, year) × RR predisposition × RR HRT × RRdensity + AR previous\nYong et al, 2022136 Supplemental Appendix 2: Natural History\n\n\n\nIncidence of tumour type by age groupc\n\n\nDCIS0–54 y: 19%55–64 y: 10%65–69 y: 16%70–79 y: 11%80+ y: 2%Invasive cancer0–54 y: 81%55–64 y: 90%65–69 y: 84%70–79 y: 89%80+ y: 98%\nYong et al, 2022136 Supplemental Appendix 2: Natural History Table 2\n\n\n\n\nTumour growth\nGompertz distribution described byd d(t) = d0([dmax/d0](1-exp[αt]))\nYong et al, 2022136 Supplemental Appendix 2: Natural History Figure 2 and Table 5 (equation coefficients)\n\n\n\nTumour spread\n\nSpread to lymph nodes Number of positive nodes affected is estimated by the size and growth rate of the tumour, years since tumour onset described bye:λ(t)=μN(b1 + b2V[t] + b3V′[t])\nYong et al, 2022136 Supplemental Appendix 2: Natural History; equation developed from the CISNET-Wisconsin model161,289\n\n\n\n\n\n\nMetastasis\nSpread beyond the breast depends on the tumour size and number of positive nodes (N*) described byf:hazard of metastasis = μM* k(tumour size, N*)\nYong et al, 2022 136 Supplemental Appendix 2: Natural History\n\n\nCancer detection, staging, and tumour biologya\n\nProbability of clinical detection of tumour\nDetermined by tumour size\nYong et al, 2022136 Supplemental Appendix 3: Cancer detection, staging and tumour biology Table 7\n\n\n\n\nStage at detectiong\n\nAssigned based on tumour size (T), nodal status (N) and metastasis (M)\nAmerican Joint Committee on Cancer (AJCC) version 7 classification290\n\n\n\n\nTumour biology: hormone receptor status, HER2 status and grade\nEstimated by tumour size, nodal involvement, metastatic status, and age of woman at tumour detection\nCanadian Cancer Registry140\n\n\n\nDisease progression\nTime to disease progression\nEstimated using Weibull regression models, adjusted to years since diagnosis, age, grade, hormone status, HER2 status, screening status, method of detection, and variable interactions\nYong et al, 2022136 Supplemental Appendix 5: Disease Progression Figure 6\n\n\n\n\nOpen in a new tab\n\nAbbreviations: AR, adjusted risk; CISNET, Cancer Intervention and Surveillance Modeling Network; CSQI, Cancer System Quality Index; DCIS, ductal carcinoma in situ; HER2, human epidermal growth factor receptor 2; HRT, hormone replacement therapy; OBSP, Ontario Breast Screening Program; RR, relative risk; Wisconsin model, University of Wisconsin Breast Cancer Epidemiology Simulation Model.\n\naThe natural history of breast cancer component of the OncoSim model and corresponding inputs (including tumour onset, growth, spread and metastasis, and clinical detection) were adapted from the Wisconsin model289 and calibrated to the incidence of cancer by age group and year in the National Cancer Incidence Reporting System (1969–1991), the Canadian Cancer Registry (1992–2013) and the Canadian Breast Cancer Screening Database (2007–2008).\n\n\nbOncogenesis rate or tumour onset is calculated by the baseline term, which is the assumed hazard of developing an occult tumour based on age and year for all simulated women, multiplied by the increased risk of breast cancer due to high breast density (RRdensity, women with dense breasts vs. without dense breasts).\n\n\ncOnce a tumour is simulated (oncogenesis), the model determines the tumour type (DCIS or invasive) using incidence of tumour type by age group.\n\n\ndTumours are assumed to grow according to a Gompertz distribution that estimates the tumour diameter (d, in cm) as a function of years since tumour onset (t), scaled to the maximum diameter allowed for a particular tumour type (dmax), where d0 is the diameter of the tumour at occult onset (0.2 cm) and a represents the tumour growth rate (model fitting).\n\n\neInvasive tumour can spread into the lymph nodes in which the spread (number of positive nodes, λ) is estimated by the size and growth rate of the tumour and years since tumour onset (t), where μN is the random term drawn at time of tumour onset that allows for heterogeneity of tumours to generate positive nodes (Yong et al,136 Supplemental Appendix 2, Natural History Table 6); b1, b2, and b3 are coefficients estimated through calibration of natural history; V(t) is the volume of the spherical tumour; and V'(t) represents the growth rate of the volume, and is the derivative of V(t).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 1 presents the PRISMA flow diagram for the clinical literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1: PRISMA Flow Diagram—Clinical Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 presents the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram for the economic literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2: PRISMA Flow Diagram—Economic Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "ONE-WAY SENSITIVITY ANALYSES\nSupplemental Screening With Handheld Ultrasound as an Adjunct to Mammography For supplemental screening with handheld ultrasound for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone and the sensitivity of supplemental screening with ultrasound (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 3: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With Handheld Ultrasound for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Supplemental Screening With MRI as an Adjunct to Mammography\nFor supplemental screening with MRI for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone or of supplemental screening with MRI, the cost of MRI screening and the RR of breast cancer (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Figure 4: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With MRI for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the relative risk of breast cancer for people with heterogeneously dense breasts compared to people with scattered areas of fibroglandular density. (B) For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI and an increase in the sensitivity of mammography alone. and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the RR of breast cancer for people with heterogeneously dense breasts (i.e., 1.51 and 1.75 for the lower and upper bound of the 95% CI, respectively, vs. 1.62 for the reference case) and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI (i.e., 88% for the lower bound of the 95% CI vs. 95% for the reference case), and an increase in the sensitivity of mammography alone (i.e., 70% for the upper bound of the 95% CI vs. 61% for the reference case; Figure 4B).Supplemental Screening With DBT as an Adjunct to Mammography\nFor supplemental screening with DBT for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone, the RR of breast cancer, and the sensitivity of supplemental screening with DBT (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 5: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With DBT for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 6 presents the budget impact model schematic.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 6: Schematic Model of Budget Impact.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 7 presents the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram for the qualitative literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7: PRISMA Flow Diagram—Qualitative Evidence Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "However, previous studies have cited that the Norwegian Ministry of Health and Care Services compare estimated ICERs to a value of 275,000 NOK ($33,805 USD) to 500,000 NOK ($61,464 USD)123–125\n\n\n\nLee et al, 2015,121 United States\nHeterogeneously and extremely dense breasts\nCUA and CEA: cost-effectiveICER $53,893 USD/QALY for biennial mammography supplemented by DBT compared to mammography aloneCommonly accepted cost-effectiveness value: $100,000 USD/QALY\n\n\n\nOpen in a new tab\nAbbreviations: ABUS, automated breast ultrasound; CEA, cost-effectiveness analysis; CUA, cost-utility analysis; DBT, digital breast tomosynthesis; ICER, incremental cost-effectiveness ratio; MRI, magnetic resonance imaging; NICE, National for Health and Care Excellence; QALY, quality-adjusted life-year; NOK, Norwegian kroner.Appendix 9: Model Input Parameters Prepopulated in the OncoSim-Breast Model\nTable A17:\nInputs for Demographic Characteristics, Natural History of Breast Cancer, Detection, and Disease Progression Used in the OncoSim-Breast Model\n\n\nModel parameter\n\nValue\nSource\n\n\n\nDemographic characteristics\nAge distribution of women in Ontario\nPrepopulated in the OncoSim model\nStatistics Canada population and demography statistics136\n\n\n\n\nAll-cause mortality\nPrepopulated in the OncoSim model\nCanadian life tables288\n\n\n\n\nScreening participation and retention rate\n64.81% (screened through the OBSP)\nCSQI 2020 Ontario Cancer System Performance report139\n\n\n\nNatural history of breast cancera\n\nOccult tumour onset (oncogenesis)\nOncogenesis rateb = baseline (age, year) × RR predisposition × RR HRT × RRdensity + AR previous\nYong et al, 2022136 Supplemental Appendix 2: Natural History\n\n\n\nIncidence of tumour type by age groupc\n\n\nDCIS0–54 y: 19%55–64 y: 10%65–69 y: 16%70–79 y: 11%80+ y: 2%Invasive cancer0–54 y: 81%55–64 y: 90%65–69 y: 84%70–79 y: 89%80+ y: 98%\nYong et al, 2022136 Supplemental Appendix 2: Natural History Table 2\n\n\n\n\nTumour growth\nGompertz distribution described byd d(t) = d0([dmax/d0](1-exp[αt]))\nYong et al, 2022136 Supplemental Appendix 2: Natural History Figure 2 and Table 5 (equation coefficients)\n\n\n\nTumour spread\n\nSpread to lymph nodes Number of positive nodes affected is estimated by the size and growth rate of the tumour, years since tumour onset described bye:λ(t)=μN(b1 + b2V[t] + b3V′[t])\nYong et al, 2022136 Supplemental Appendix 2: Natural History; equation developed from the CISNET-Wisconsin model161,289\n\n\n\n\n\n\nMetastasis\nSpread beyond the breast depends on the tumour size and number of positive nodes (N*) described byf:hazard of metastasis = μM* k(tumour size, N*)\nYong et al, 2022 136 Supplemental Appendix 2: Natural History\n\n\nCancer detection, staging, and tumour biologya\n\nProbability of clinical detection of tumour\nDetermined by tumour size\nYong et al, 2022136 Supplemental Appendix 3: Cancer detection, staging and tumour biology Table 7\n\n\n\n\nStage at detectiong\n\nAssigned based on tumour size (T), nodal status (N) and metastasis (M)\nAmerican Joint Committee on Cancer (AJCC) version 7 classification290\n\n\n\n\nTumour biology: hormone receptor status, HER2 status and grade\nEstimated by tumour size, nodal involvement, metastatic status, and age of woman at tumour detection\nCanadian Cancer Registry140\n\n\n\nDisease progression\nTime to disease progression\nEstimated using Weibull regression models, adjusted to years since diagnosis, age, grade, hormone status, HER2 status, screening status, method of detection, and variable interactions\nYong et al, 2022136 Supplemental Appendix 5: Disease Progression Figure 6\n\n\n\n\nOpen in a new tab\n\nAbbreviations: AR, adjusted risk; CISNET, Cancer Intervention and Surveillance Modeling Network; CSQI, Cancer System Quality Index; DCIS, ductal carcinoma in situ; HER2, human epidermal growth factor receptor 2; HRT, hormone replacement therapy; OBSP, Ontario Breast Screening Program; RR, relative risk; Wisconsin model, University of Wisconsin Breast Cancer Epidemiology Simulation Model.\n\naThe natural history of breast cancer component of the OncoSim model and corresponding inputs (including tumour onset, growth, spread and metastasis, and clinical detection) were adapted from the Wisconsin model289 and calibrated to the incidence of cancer by age group and year in the National Cancer Incidence Reporting System (1969–1991), the Canadian Cancer Registry (1992–2013) and the Canadian Breast Cancer Screening Database (2007–2008).\n\n\nbOncogenesis rate or tumour onset is calculated by the baseline term, which is the assumed hazard of developing an occult tumour based on age and year for all simulated women, multiplied by the increased risk of breast cancer due to high breast density (RRdensity, women with dense breasts vs. without dense breasts).\n\n\ncOnce a tumour is simulated (oncogenesis), the model determines the tumour type (DCIS or invasive) using incidence of tumour type by age group.\n\n\ndTumours are assumed to grow according to a Gompertz distribution that estimates the tumour diameter (d, in cm) as a function of years since tumour onset (t), scaled to the maximum diameter allowed for a particular tumour type (dmax), where d0 is the diameter of the tumour at occult onset (0.2 cm) and a represents the tumour growth rate (model fitting).\n\n\neInvasive tumour can spread into the lymph nodes in which the spread (number of positive nodes, λ) is estimated by the size and growth rate of the tumour and years since tumour onset (t), where μN is the random term drawn at time of tumour onset that allows for heterogeneity of tumours to generate positive nodes (Yong et al,136 Supplemental Appendix 2, Natural History Table 6); b1, b2, and b3 are coefficients estimated through calibration of natural history; V(t) is the volume of the spherical tumour; and V'(t) represents the growth rate of the volume, and is the derivative of V(t).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 1 presents the PRISMA flow diagram for the clinical literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1: PRISMA Flow Diagram—Clinical Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 presents the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram for the economic literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2: PRISMA Flow Diagram—Economic Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "ONE-WAY SENSITIVITY ANALYSES\nSupplemental Screening With Handheld Ultrasound as an Adjunct to Mammography For supplemental screening with handheld ultrasound for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone and the sensitivity of supplemental screening with ultrasound (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 3: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With Handheld Ultrasound for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Supplemental Screening With MRI as an Adjunct to Mammography\nFor supplemental screening with MRI for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone or of supplemental screening with MRI, the cost of MRI screening and the RR of breast cancer (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Figure 4: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With MRI for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the relative risk of breast cancer for people with heterogeneously dense breasts compared to people with scattered areas of fibroglandular density. (B) For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI and an increase in the sensitivity of mammography alone. and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the RR of breast cancer for people with heterogeneously dense breasts (i.e., 1.51 and 1.75 for the lower and upper bound of the 95% CI, respectively, vs. 1.62 for the reference case) and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI (i.e., 88% for the lower bound of the 95% CI vs. 95% for the reference case), and an increase in the sensitivity of mammography alone (i.e., 70% for the upper bound of the 95% CI vs. 61% for the reference case; Figure 4B).Supplemental Screening With DBT as an Adjunct to Mammography\nFor supplemental screening with DBT for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone, the RR of breast cancer, and the sensitivity of supplemental screening with DBT (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 5: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With DBT for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 6 presents the budget impact model schematic.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 6: Schematic Model of Budget Impact.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 7 presents the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram for the qualitative literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7: PRISMA Flow Diagram—Qualitative Evidence Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "However, previous studies have cited that the Norwegian Ministry of Health and Care Services compare estimated ICERs to a value of 275,000 NOK ($33,805 USD) to 500,000 NOK ($61,464 USD)123–125\n\n\n\nLee et al, 2015,121 United States\nHeterogeneously and extremely dense breasts\nCUA and CEA: cost-effectiveICER $53,893 USD/QALY for biennial mammography supplemented by DBT compared to mammography aloneCommonly accepted cost-effectiveness value: $100,000 USD/QALY\n\n\n\nOpen in a new tab\nAbbreviations: ABUS, automated breast ultrasound; CEA, cost-effectiveness analysis; CUA, cost-utility analysis; DBT, digital breast tomosynthesis; ICER, incremental cost-effectiveness ratio; MRI, magnetic resonance imaging; NICE, National for Health and Care Excellence; QALY, quality-adjusted life-year; NOK, Norwegian kroner.Appendix 9: Model Input Parameters Prepopulated in the OncoSim-Breast Model\nTable A17:\nInputs for Demographic Characteristics, Natural History of Breast Cancer, Detection, and Disease Progression Used in the OncoSim-Breast Model\n\n\nModel parameter\n\nValue\nSource\n\n\n\nDemographic characteristics\nAge distribution of women in Ontario\nPrepopulated in the OncoSim model\nStatistics Canada population and demography statistics136\n\n\n\n\nAll-cause mortality\nPrepopulated in the OncoSim model\nCanadian life tables288\n\n\n\n\nScreening participation and retention rate\n64.81% (screened through the OBSP)\nCSQI 2020 Ontario Cancer System Performance report139\n\n\n\nNatural history of breast cancera\n\nOccult tumour onset (oncogenesis)\nOncogenesis rateb = baseline (age, year) × RR predisposition × RR HRT × RRdensity + AR previous\nYong et al, 2022136 Supplemental Appendix 2: Natural History\n\n\n\nIncidence of tumour type by age groupc\n\n\nDCIS0–54 y: 19%55–64 y: 10%65–69 y: 16%70–79 y: 11%80+ y: 2%Invasive cancer0–54 y: 81%55–64 y: 90%65–69 y: 84%70–79 y: 89%80+ y: 98%\nYong et al, 2022136 Supplemental Appendix 2: Natural History Table 2\n\n\n\n\nTumour growth\nGompertz distribution described byd d(t) = d0([dmax/d0](1-exp[αt]))\nYong et al, 2022136 Supplemental Appendix 2: Natural History Figure 2 and Table 5 (equation coefficients)\n\n\n\nTumour spread\n\nSpread to lymph nodes Number of positive nodes affected is estimated by the size and growth rate of the tumour, years since tumour onset described bye:λ(t)=μN(b1 + b2V[t] + b3V′[t])\nYong et al, 2022136 Supplemental Appendix 2: Natural History; equation developed from the CISNET-Wisconsin model161,289\n\n\n\n\n\n\nMetastasis\nSpread beyond the breast depends on the tumour size and number of positive nodes (N*) described byf:hazard of metastasis = μM* k(tumour size, N*)\nYong et al, 2022 136 Supplemental Appendix 2: Natural History\n\n\nCancer detection, staging, and tumour biologya\n\nProbability of clinical detection of tumour\nDetermined by tumour size\nYong et al, 2022136 Supplemental Appendix 3: Cancer detection, staging and tumour biology Table 7\n\n\n\n\nStage at detectiong\n\nAssigned based on tumour size (T), nodal status (N) and metastasis (M)\nAmerican Joint Committee on Cancer (AJCC) version 7 classification290\n\n\n\n\nTumour biology: hormone receptor status, HER2 status and grade\nEstimated by tumour size, nodal involvement, metastatic status, and age of woman at tumour detection\nCanadian Cancer Registry140\n\n\n\nDisease progression\nTime to disease progression\nEstimated using Weibull regression models, adjusted to years since diagnosis, age, grade, hormone status, HER2 status, screening status, method of detection, and variable interactions\nYong et al, 2022136 Supplemental Appendix 5: Disease Progression Figure 6\n\n\n\n\nOpen in a new tab\n\nAbbreviations: AR, adjusted risk; CISNET, Cancer Intervention and Surveillance Modeling Network; CSQI, Cancer System Quality Index; DCIS, ductal carcinoma in situ; HER2, human epidermal growth factor receptor 2; HRT, hormone replacement therapy; OBSP, Ontario Breast Screening Program; RR, relative risk; Wisconsin model, University of Wisconsin Breast Cancer Epidemiology Simulation Model.\n\naThe natural history of breast cancer component of the OncoSim model and corresponding inputs (including tumour onset, growth, spread and metastasis, and clinical detection) were adapted from the Wisconsin model289 and calibrated to the incidence of cancer by age group and year in the National Cancer Incidence Reporting System (1969–1991), the Canadian Cancer Registry (1992–2013) and the Canadian Breast Cancer Screening Database (2007–2008).\n\n\nbOncogenesis rate or tumour onset is calculated by the baseline term, which is the assumed hazard of developing an occult tumour based on age and year for all simulated women, multiplied by the increased risk of breast cancer due to high breast density (RRdensity, women with dense breasts vs. without dense breasts).\n\n\ncOnce a tumour is simulated (oncogenesis), the model determines the tumour type (DCIS or invasive) using incidence of tumour type by age group.\n\n\ndTumours are assumed to grow according to a Gompertz distribution that estimates the tumour diameter (d, in cm) as a function of years since tumour onset (t), scaled to the maximum diameter allowed for a particular tumour type (dmax), where d0 is the diameter of the tumour at occult onset (0.2 cm) and a represents the tumour growth rate (model fitting).\n\n\neInvasive tumour can spread into the lymph nodes in which the spread (number of positive nodes, λ) is estimated by the size and growth rate of the tumour and years since tumour onset (t), where μN is the random term drawn at time of tumour onset that allows for heterogeneity of tumours to generate positive nodes (Yong et al,136 Supplemental Appendix 2, Natural History Table 6); b1, b2, and b3 are coefficients estimated through calibration of natural history; V(t) is the volume of the spherical tumour; and V'(t) represents the growth rate of the volume, and is the derivative of V(t).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 1 presents the PRISMA flow diagram for the clinical literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1: PRISMA Flow Diagram—Clinical Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1 presents the PRISMA flow diagram for the clinical literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1: PRISMA Flow Diagram—Clinical Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1 presents the PRISMA flow diagram for the clinical literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1: PRISMA Flow Diagram—Clinical Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 1 presents the PRISMA flow diagram for the clinical literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 presents the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram for the economic literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2: PRISMA Flow Diagram—Economic Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2 presents the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram for the economic literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2: PRISMA Flow Diagram—Economic Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2 presents the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram for the economic literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2: PRISMA Flow Diagram—Economic Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2 presents the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram for the economic literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "ONE-WAY SENSITIVITY ANALYSES\nSupplemental Screening With Handheld Ultrasound as an Adjunct to Mammography For supplemental screening with handheld ultrasound for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone and the sensitivity of supplemental screening with ultrasound (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 3: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With Handheld Ultrasound for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Supplemental Screening With MRI as an Adjunct to Mammography\nFor supplemental screening with MRI for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone or of supplemental screening with MRI, the cost of MRI screening and the RR of breast cancer (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Figure 4: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With MRI for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the relative risk of breast cancer for people with heterogeneously dense breasts compared to people with scattered areas of fibroglandular density. (B) For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI and an increase in the sensitivity of mammography alone. and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the RR of breast cancer for people with heterogeneously dense breasts (i.e., 1.51 and 1.75 for the lower and upper bound of the 95% CI, respectively, vs. 1.62 for the reference case) and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI (i.e., 88% for the lower bound of the 95% CI vs. 95% for the reference case), and an increase in the sensitivity of mammography alone (i.e., 70% for the upper bound of the 95% CI vs. 61% for the reference case; Figure 4B).Supplemental Screening With DBT as an Adjunct to Mammography\nFor supplemental screening with DBT for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone, the RR of breast cancer, and the sensitivity of supplemental screening with DBT (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 5: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With DBT for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "ONE-WAY SENSITIVITY ANALYSES\nSupplemental Screening With Handheld Ultrasound as an Adjunct to Mammography For supplemental screening with handheld ultrasound for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone and the sensitivity of supplemental screening with ultrasound (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 3: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With Handheld Ultrasound for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Supplemental Screening With MRI as an Adjunct to Mammography\nFor supplemental screening with MRI for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone or of supplemental screening with MRI, the cost of MRI screening and the RR of breast cancer (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Figure 4: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With MRI for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the relative risk of breast cancer for people with heterogeneously dense breasts compared to people with scattered areas of fibroglandular density. (B) For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI and an increase in the sensitivity of mammography alone. and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the RR of breast cancer for people with heterogeneously dense breasts (i.e., 1.51 and 1.75 for the lower and upper bound of the 95% CI, respectively, vs. 1.62 for the reference case) and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI (i.e., 88% for the lower bound of the 95% CI vs. 95% for the reference case), and an increase in the sensitivity of mammography alone (i.e., 70% for the upper bound of the 95% CI vs. 61% for the reference case; Figure 4B).Supplemental Screening With DBT as an Adjunct to Mammography\nFor supplemental screening with DBT for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone, the RR of breast cancer, and the sensitivity of supplemental screening with DBT (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 5: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With DBT for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "ONE-WAY SENSITIVITY ANALYSES\nSupplemental Screening With Handheld Ultrasound as an Adjunct to Mammography For supplemental screening with handheld ultrasound for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone and the sensitivity of supplemental screening with ultrasound (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 3: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With Handheld Ultrasound for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Supplemental Screening With MRI as an Adjunct to Mammography\nFor supplemental screening with MRI for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone or of supplemental screening with MRI, the cost of MRI screening and the RR of breast cancer (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Figure 4: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With MRI for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the relative risk of breast cancer for people with heterogeneously dense breasts compared to people with scattered areas of fibroglandular density. (B) For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI and an increase in the sensitivity of mammography alone. and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the RR of breast cancer for people with heterogeneously dense breasts (i.e., 1.51 and 1.75 for the lower and upper bound of the 95% CI, respectively, vs. 1.62 for the reference case) and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI (i.e., 88% for the lower bound of the 95% CI vs. 95% for the reference case), and an increase in the sensitivity of mammography alone (i.e., 70% for the upper bound of the 95% CI vs. 61% for the reference case; Figure 4B).Supplemental Screening With DBT as an Adjunct to Mammography\nFor supplemental screening with DBT for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone, the RR of breast cancer, and the sensitivity of supplemental screening with DBT (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 5: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With DBT for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "ONE-WAY SENSITIVITY ANALYSES\nSupplemental Screening With Handheld Ultrasound as an Adjunct to Mammography For supplemental screening with handheld ultrasound for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone and the sensitivity of supplemental screening with ultrasound (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 3: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With Handheld Ultrasound for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Supplemental Screening With MRI as an Adjunct to Mammography\nFor supplemental screening with MRI for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone or of supplemental screening with MRI, the cost of MRI screening and the RR of breast cancer (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Figure 4: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With MRI for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the relative risk of breast cancer for people with heterogeneously dense breasts compared to people with scattered areas of fibroglandular density. (B) For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI and an increase in the sensitivity of mammography alone. and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the RR of breast cancer for people with heterogeneously dense breasts (i.e., 1.51 and 1.75 for the lower and upper bound of the 95% CI, respectively, vs. 1.62 for the reference case) and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI (i.e., 88% for the lower bound of the 95% CI vs. 95% for the reference case), and an increase in the sensitivity of mammography alone (i.e., 70% for the upper bound of the 95% CI vs. 61% for the reference case; Figure 4B).Supplemental Screening With DBT as an Adjunct to Mammography\nFor supplemental screening with DBT for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone, the RR of breast cancer, and the sensitivity of supplemental screening with DBT (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 5: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With DBT for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Supplemental Screening With Handheld Ultrasound as an Adjunct to Mammography For supplemental screening with handheld ultrasound for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone and the sensitivity of supplemental screening with ultrasound (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Supplemental Screening With MRI as an Adjunct to Mammography\nFor supplemental screening with MRI for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone or of supplemental screening with MRI, the cost of MRI screening and the RR of breast cancer (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Figure 4: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With MRI for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the relative risk of breast cancer for people with heterogeneously dense breasts compared to people with scattered areas of fibroglandular density. (B) For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI and an increase in the sensitivity of mammography alone. and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the RR of breast cancer for people with heterogeneously dense breasts (i.e., 1.51 and 1.75 for the lower and upper bound of the 95% CI, respectively, vs. 1.62 for the reference case) and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI (i.e., 88% for the lower bound of the 95% CI vs. 95% for the reference case), and an increase in the sensitivity of mammography alone (i.e., 70% for the upper bound of the 95% CI vs. 61% for the reference case; Figure 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For supplemental screening with MRI for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone or of supplemental screening with MRI, the cost of MRI screening and the RR of breast cancer (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the relative risk of breast cancer for people with heterogeneously dense breasts compared to people with scattered areas of fibroglandular density. (B) For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI and an increase in the sensitivity of mammography alone. and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Estimated ICERs were also impacted by the RR of breast cancer for people with heterogeneously dense breasts (i.e., 1.51 and 1.75 for the lower and upper bound of the 95% CI, respectively, vs. 1.62 for the reference case) and extremely dense breasts (i.e., 1.84 and 2.26 for the lower and upper bound of the 95% CI, respectively, vs. 2.04 for the reference case) compared to people with scattered areas of fibroglandular density (BI-RADS B; Figure 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For people with extremely dense breasts, the ICERs were mostly impacted (increased) by a decrease in the sensitivity of mammography plus supplemental MRI (i.e., 88% for the lower bound of the 95% CI vs. 95% for the reference case), and an increase in the sensitivity of mammography alone (i.e., 70% for the upper bound of the 95% CI vs. 61% for the reference case; Figure 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Supplemental Screening With DBT as an Adjunct to Mammography\nFor supplemental screening with DBT for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone, the RR of breast cancer, and the sensitivity of supplemental screening with DBT (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 5: Tornado Diagram—Sensitivity Analysis, Supplemental Screening With DBT for People With Dense Breasts and Extremely Dense Breasts.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "For supplemental screening with DBT for people with dense breasts and extremely dense breasts, the estimated ICERs were impacted by changes to the sensitivity of mammography alone, the RR of breast cancer, and the sensitivity of supplemental screening with DBT (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 6 presents the budget impact model schematic.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 6: Schematic Model of Budget Impact.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 6 presents the budget impact model schematic.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 6: Schematic Model of Budget Impact.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 6 presents the budget impact model schematic.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 6: Schematic Model of Budget Impact.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 6 presents the budget impact model schematic.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 7 presents the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram for the qualitative literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7: PRISMA Flow Diagram—Qualitative Evidence Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7 presents the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram for the qualitative literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7: PRISMA Flow Diagram—Qualitative Evidence Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7 presents the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram for the qualitative literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7: PRISMA Flow Diagram—Qualitative Evidence Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7 presents the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram for the qualitative literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7: PRISMA Flow Diagram—Qualitative Evidence Search Strategy.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7 presents the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram for the qualitative literature search.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "However, previous studies have cited that the Norwegian Ministry of Health and Care Services compare estimated ICERs to a value of 275,000 NOK ($33,805 USD) to 500,000 NOK ($61,464 USD)123–125\n\n\n\nLee et al, 2015,121 United States\nHeterogeneously and extremely dense breasts\nCUA and CEA: cost-effectiveICER $53,893 USD/QALY for biennial mammography supplemented by DBT compared to mammography aloneCommonly accepted cost-effectiveness value: $100,000 USD/QALY\n\n\n\nOpen in a new tab\nAbbreviations: ABUS, automated breast ultrasound; CEA, cost-effectiveness analysis; CUA, cost-utility analysis; DBT, digital breast tomosynthesis; ICER, incremental cost-effectiveness ratio; MRI, magnetic resonance imaging; NICE, National for Health and Care Excellence; QALY, quality-adjusted life-year; NOK, Norwegian kroner.Appendix 9: Model Input Parameters Prepopulated in the OncoSim-Breast Model\nTable A17:\nInputs for Demographic Characteristics, Natural History of Breast Cancer, Detection, and Disease Progression Used in the OncoSim-Breast Model\n\n\nModel parameter\n\nValue\nSource\n\n\n\nDemographic characteristics\nAge distribution of women in Ontario\nPrepopulated in the OncoSim model\nStatistics Canada population and demography statistics136\n\n\n\n\nAll-cause mortality\nPrepopulated in the OncoSim model\nCanadian life tables288\n\n\n\n\nScreening participation and retention rate\n64.81% (screened through the OBSP)\nCSQI 2020 Ontario Cancer System Performance report139\n\n\n\nNatural history of breast cancera\n\nOccult tumour onset (oncogenesis)\nOncogenesis rateb = baseline (age, year) × RR predisposition × RR HRT × RRdensity + AR previous\nYong et al, 2022136 Supplemental Appendix 2: Natural History\n\n\n\nIncidence of tumour type by age groupc\n\n\nDCIS0–54 y: 19%55–64 y: 10%65–69 y: 16%70–79 y: 11%80+ y: 2%Invasive cancer0–54 y: 81%55–64 y: 90%65–69 y: 84%70–79 y: 89%80+ y: 98%\nYong et al, 2022136 Supplemental Appendix 2: Natural History Table 2\n\n\n\n\nTumour growth\nGompertz distribution described byd d(t) = d0([dmax/d0](1-exp[αt]))\nYong et al, 2022136 Supplemental Appendix 2: Natural History Figure 2 and Table 5 (equation coefficients)\n\n\n\nTumour spread\n\nSpread to lymph nodes Number of positive nodes affected is estimated by the size and growth rate of the tumour, years since tumour onset described bye:λ(t)=μN(b1 + b2V[t] + b3V′[t])\nYong et al, 2022136 Supplemental Appendix 2: Natural History; equation developed from the CISNET-Wisconsin model161,289\n\n\n\n\n\n\nMetastasis\nSpread beyond the breast depends on the tumour size and number of positive nodes (N*) described byf:hazard of metastasis = μM* k(tumour size, N*)\nYong et al, 2022 136 Supplemental Appendix 2: Natural History\n\n\nCancer detection, staging, and tumour biologya\n\nProbability of clinical detection of tumour\nDetermined by tumour size\nYong et al, 2022136 Supplemental Appendix 3: Cancer detection, staging and tumour biology Table 7\n\n\n\n\nStage at detectiong\n\nAssigned based on tumour size (T), nodal status (N) and metastasis (M)\nAmerican Joint Committee on Cancer (AJCC) version 7 classification290\n\n\n\n\nTumour biology: hormone receptor status, HER2 status and grade\nEstimated by tumour size, nodal involvement, metastatic status, and age of woman at tumour detection\nCanadian Cancer Registry140\n\n\n\nDisease progression\nTime to disease progression\nEstimated using Weibull regression models, adjusted to years since diagnosis, age, grade, hormone status, HER2 status, screening status, method of detection, and variable interactions\nYong et al, 2022136 Supplemental Appendix 5: Disease Progression Figure 6\n\n\n\n\nOpen in a new tab\n\nAbbreviations: AR, adjusted risk; CISNET, Cancer Intervention and Surveillance Modeling Network; CSQI, Cancer System Quality Index; DCIS, ductal carcinoma in situ; HER2, human epidermal growth factor receptor 2; HRT, hormone replacement therapy; OBSP, Ontario Breast Screening Program; RR, relative risk; Wisconsin model, University of Wisconsin Breast Cancer Epidemiology Simulation Model.\n\naThe natural history of breast cancer component of the OncoSim model and corresponding inputs (including tumour onset, growth, spread and metastasis, and clinical detection) were adapted from the Wisconsin model289 and calibrated to the incidence of cancer by age group and year in the National Cancer Incidence Reporting System (1969–1991), the Canadian Cancer Registry (1992–2013) and the Canadian Breast Cancer Screening Database (2007–2008).\n\n\nbOncogenesis rate or tumour onset is calculated by the baseline term, which is the assumed hazard of developing an occult tumour based on age and year for all simulated women, multiplied by the increased risk of breast cancer due to high breast density (RRdensity, women with dense breasts vs. without dense breasts).\n\n\ncOnce a tumour is simulated (oncogenesis), the model determines the tumour type (DCIS or invasive) using incidence of tumour type by age group.\n\n\ndTumours are assumed to grow according to a Gompertz distribution that estimates the tumour diameter (d, in cm) as a function of years since tumour onset (t), scaled to the maximum diameter allowed for a particular tumour type (dmax), where d0 is the diameter of the tumour at occult onset (0.2 cm) and a represents the tumour growth rate (model fitting).\n\n\neInvasive tumour can spread into the lymph nodes in which the spread (number of positive nodes, λ) is estimated by the size and growth rate of the tumour and years since tumour onset (t), where μN is the random term drawn at time of tumour onset that allows for heterogeneity of tumours to generate positive nodes (Yong et al,136 Supplemental Appendix 2, Natural History Table 6); b1, b2, and b3 are coefficients estimated through calibration of natural history; V(t) is the volume of the spherical tumour; and V'(t) represents the growth rate of the volume, and is the derivative of V(t).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Appendix 9: Model Input Parameters Prepopulated in the OncoSim-Breast Model\nTable A17:\nInputs for Demographic Characteristics, Natural History of Breast Cancer, Detection, and Disease Progression Used in the OncoSim-Breast Model\n\n\nModel parameter\n\nValue\nSource\n\n\n\nDemographic characteristics\nAge distribution of women in Ontario\nPrepopulated in the OncoSim model\nStatistics Canada population and demography statistics136\n\n\n\n\nAll-cause mortality\nPrepopulated in the OncoSim model\nCanadian life tables288\n\n\n\n\nScreening participation and retention rate\n64.81% (screened through the OBSP)\nCSQI 2020 Ontario Cancer System Performance report139\n\n\n\nNatural history of breast cancera\n\nOccult tumour onset (oncogenesis)\nOncogenesis rateb = baseline (age, year) × RR predisposition × RR HRT × RRdensity + AR previous\nYong et al, 2022136 Supplemental Appendix 2: Natural History\n\n\n\nIncidence of tumour type by age groupc\n\n\nDCIS0–54 y: 19%55–64 y: 10%65–69 y: 16%70–79 y: 11%80+ y: 2%Invasive cancer0–54 y: 81%55–64 y: 90%65–69 y: 84%70–79 y: 89%80+ y: 98%\nYong et al, 2022136 Supplemental Appendix 2: Natural History Table 2\n\n\n\n\nTumour growth\nGompertz distribution described byd d(t) = d0([dmax/d0](1-exp[αt]))\nYong et al, 2022136 Supplemental Appendix 2: Natural History Figure 2 and Table 5 (equation coefficients)\n\n\n\nTumour spread\n\nSpread to lymph nodes Number of positive nodes affected is estimated by the size and growth rate of the tumour, years since tumour onset described bye:λ(t)=μN(b1 + b2V[t] + b3V′[t])\nYong et al, 2022136 Supplemental Appendix 2: Natural History; equation developed from the CISNET-Wisconsin model161,289\n\n\n\n\n\n\nMetastasis\nSpread beyond the breast depends on the tumour size and number of positive nodes (N*) described byf:hazard of metastasis = μM* k(tumour size, N*)\nYong et al, 2022 136 Supplemental Appendix 2: Natural History\n\n\nCancer detection, staging, and tumour biologya\n\nProbability of clinical detection of tumour\nDetermined by tumour size\nYong et al, 2022136 Supplemental Appendix 3: Cancer detection, staging and tumour biology Table 7\n\n\n\n\nStage at detectiong\n\nAssigned based on tumour size (T), nodal status (N) and metastasis (M)\nAmerican Joint Committee on Cancer (AJCC) version 7 classification290\n\n\n\n\nTumour biology: hormone receptor status, HER2 status and grade\nEstimated by tumour size, nodal involvement, metastatic status, and age of woman at tumour detection\nCanadian Cancer Registry140\n\n\n\nDisease progression\nTime to disease progression\nEstimated using Weibull regression models, adjusted to years since diagnosis, age, grade, hormone status, HER2 status, screening status, method of detection, and variable interactions\nYong et al, 2022136 Supplemental Appendix 5: Disease Progression Figure 6\n\n\n\n\nOpen in a new tab\n\nAbbreviations: AR, adjusted risk; CISNET, Cancer Intervention and Surveillance Modeling Network; CSQI, Cancer System Quality Index; DCIS, ductal carcinoma in situ; HER2, human epidermal growth factor receptor 2; HRT, hormone replacement therapy; OBSP, Ontario Breast Screening Program; RR, relative risk; Wisconsin model, University of Wisconsin Breast Cancer Epidemiology Simulation Model.\n\naThe natural history of breast cancer component of the OncoSim model and corresponding inputs (including tumour onset, growth, spread and metastasis, and clinical detection) were adapted from the Wisconsin model289 and calibrated to the incidence of cancer by age group and year in the National Cancer Incidence Reporting System (1969–1991), the Canadian Cancer Registry (1992–2013) and the Canadian Breast Cancer Screening Database (2007–2008).\n\n\nbOncogenesis rate or tumour onset is calculated by the baseline term, which is the assumed hazard of developing an occult tumour based on age and year for all simulated women, multiplied by the increased risk of breast cancer due to high breast density (RRdensity, women with dense breasts vs. without dense breasts).\n\n\ncOnce a tumour is simulated (oncogenesis), the model determines the tumour type (DCIS or invasive) using incidence of tumour type by age group.\n\n\ndTumours are assumed to grow according to a Gompertz distribution that estimates the tumour diameter (d, in cm) as a function of years since tumour onset (t), scaled to the maximum diameter allowed for a particular tumour type (dmax), where d0 is the diameter of the tumour at occult onset (0.2 cm) and a represents the tumour growth rate (model fitting).\n\n\neInvasive tumour can spread into the lymph nodes in which the spread (number of positive nodes, λ) is estimated by the size and growth rate of the tumour and years since tumour onset (t), where μN is the random term drawn at time of tumour onset that allows for heterogeneity of tumours to generate positive nodes (Yong et al,136 Supplemental Appendix 2, Natural History Table 6); b1, b2, and b3 are coefficients estimated through calibration of natural history; V(t) is the volume of the spherical tumour; and V'(t) represents the growth rate of the volume, and is the derivative of V(t).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Table A17:\nInputs for Demographic Characteristics, Natural History of Breast Cancer, Detection, and Disease Progression Used in the OncoSim-Breast Model\n\n\nModel parameter\n\nValue\nSource\n\n\n\nDemographic characteristics\nAge distribution of women in Ontario\nPrepopulated in the OncoSim model\nStatistics Canada population and demography statistics136\n\n\n\n\nAll-cause mortality\nPrepopulated in the OncoSim model\nCanadian life tables288\n\n\n\n\nScreening participation and retention rate\n64.81% (screened through the OBSP)\nCSQI 2020 Ontario Cancer System Performance report139\n\n\n\nNatural history of breast cancera\n\nOccult tumour onset (oncogenesis)\nOncogenesis rateb = baseline (age, year) × RR predisposition × RR HRT × RRdensity + AR previous\nYong et al, 2022136 Supplemental Appendix 2: Natural History\n\n\n\nIncidence of tumour type by age groupc\n\n\nDCIS0–54 y: 19%55–64 y: 10%65–69 y: 16%70–79 y: 11%80+ y: 2%Invasive cancer0–54 y: 81%55–64 y: 90%65–69 y: 84%70–79 y: 89%80+ y: 98%\nYong et al, 2022136 Supplemental Appendix 2: Natural History Table 2\n\n\n\n\nTumour growth\nGompertz distribution described byd d(t) = d0([dmax/d0](1-exp[αt]))\nYong et al, 2022136 Supplemental Appendix 2: Natural History Figure 2 and Table 5 (equation coefficients)\n\n\n\nTumour spread\n\nSpread to lymph nodes Number of positive nodes affected is estimated by the size and growth rate of the tumour, years since tumour onset described bye:λ(t)=μN(b1 + b2V[t] + b3V′[t])\nYong et al, 2022136 Supplemental Appendix 2: Natural History; equation developed from the CISNET-Wisconsin model161,289\n\n\n\n\n\n\nMetastasis\nSpread beyond the breast depends on the tumour size and number of positive nodes (N*) described byf:hazard of metastasis = μM* k(tumour size, N*)\nYong et al, 2022 136 Supplemental Appendix 2: Natural History\n\n\nCancer detection, staging, and tumour biologya\n\nProbability of clinical detection of tumour\nDetermined by tumour size\nYong et al, 2022136 Supplemental Appendix 3: Cancer detection, staging and tumour biology Table 7\n\n\n\n\nStage at detectiong\n\nAssigned based on tumour size (T), nodal status (N) and metastasis (M)\nAmerican Joint Committee on Cancer (AJCC) version 7 classification290\n\n\n\n\nTumour biology: hormone receptor status, HER2 status and grade\nEstimated by tumour size, nodal involvement, metastatic status, and age of woman at tumour detection\nCanadian Cancer Registry140\n\n\n\nDisease progression\nTime to disease progression\nEstimated using Weibull regression models, adjusted to years since diagnosis, age, grade, hormone status, HER2 status, screening status, method of detection, and variable interactions\nYong et al, 2022136 Supplemental Appendix 5: Disease Progression Figure 6\n\n\n\n\nOpen in a new tab\n\nAbbreviations: AR, adjusted risk; CISNET, Cancer Intervention and Surveillance Modeling Network; CSQI, Cancer System Quality Index; DCIS, ductal carcinoma in situ; HER2, human epidermal growth factor receptor 2; HRT, hormone replacement therapy; OBSP, Ontario Breast Screening Program; RR, relative risk; Wisconsin model, University of Wisconsin Breast Cancer Epidemiology Simulation Model.\n\naThe natural history of breast cancer component of the OncoSim model and corresponding inputs (including tumour onset, growth, spread and metastasis, and clinical detection) were adapted from the Wisconsin model289 and calibrated to the incidence of cancer by age group and year in the National Cancer Incidence Reporting System (1969–1991), the Canadian Cancer Registry (1992–2013) and the Canadian Breast Cancer Screening Database (2007–2008).\n\n\nbOncogenesis rate or tumour onset is calculated by the baseline term, which is the assumed hazard of developing an occult tumour based on age and year for all simulated women, multiplied by the increased risk of breast cancer due to high breast density (RRdensity, women with dense breasts vs. without dense breasts).\n\n\ncOnce a tumour is simulated (oncogenesis), the model determines the tumour type (DCIS or invasive) using incidence of tumour type by age group.\n\n\ndTumours are assumed to grow according to a Gompertz distribution that estimates the tumour diameter (d, in cm) as a function of years since tumour onset (t), scaled to the maximum diameter allowed for a particular tumour type (dmax), where d0 is the diameter of the tumour at occult onset (0.2 cm) and a represents the tumour growth rate (model fitting).\n\n\neInvasive tumour can spread into the lymph nodes in which the spread (number of positive nodes, λ) is estimated by the size and growth rate of the tumour and years since tumour onset (t), where μN is the random term drawn at time of tumour onset that allows for heterogeneity of tumours to generate positive nodes (Yong et al,136 Supplemental Appendix 2, Natural History Table 6); b1, b2, and b3 are coefficients estimated through calibration of natural history; V(t) is the volume of the spherical tumour; and V'(t) represents the growth rate of the volume, and is the derivative of V(t).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Model parameter\n\nValue\nSource\n\n\n\nDemographic characteristics\nAge distribution of women in Ontario\nPrepopulated in the OncoSim model\nStatistics Canada population and demography statistics136\n\n\n\n\nAll-cause mortality\nPrepopulated in the OncoSim model\nCanadian life tables288\n\n\n\n\nScreening participation and retention rate\n64.81% (screened through the OBSP)\nCSQI 2020 Ontario Cancer System Performance report139\n\n\n\nNatural history of breast cancera\n\nOccult tumour onset (oncogenesis)\nOncogenesis rateb = baseline (age, year) × RR predisposition × RR HRT × RRdensity + AR previous\nYong et al, 2022136 Supplemental Appendix 2: Natural History\n\n\n\nIncidence of tumour type by age groupc\n\n\nDCIS0–54 y: 19%55–64 y: 10%65–69 y: 16%70–79 y: 11%80+ y: 2%Invasive cancer0–54 y: 81%55–64 y: 90%65–69 y: 84%70–79 y: 89%80+ y: 98%\nYong et al, 2022136 Supplemental Appendix 2: Natural History Table 2\n\n\n\n\nTumour growth\nGompertz distribution described byd d(t) = d0([dmax/d0](1-exp[αt]))\nYong et al, 2022136 Supplemental Appendix 2: Natural History Figure 2 and Table 5 (equation coefficients)\n\n\n\nTumour spread\n\nSpread to lymph nodes Number of positive nodes affected is estimated by the size and growth rate of the tumour, years since tumour onset described bye:λ(t)=μN(b1 + b2V[t] + b3V′[t])\nYong et al, 2022136 Supplemental Appendix 2: Natural History; equation developed from the CISNET-Wisconsin model161,289\n\n\n\n\n\n\nMetastasis\nSpread beyond the breast depends on the tumour size and number of positive nodes (N*) described byf:hazard of metastasis = μM* k(tumour size, N*)\nYong et al, 2022 136 Supplemental Appendix 2: Natural History\n\n\nCancer detection, staging, and tumour biologya\n\nProbability of clinical detection of tumour\nDetermined by tumour size\nYong et al, 2022136 Supplemental Appendix 3: Cancer detection, staging and tumour biology Table 7\n\n\n\n\nStage at detectiong\n\nAssigned based on tumour size (T), nodal status (N) and metastasis (M)\nAmerican Joint Committee on Cancer (AJCC) version 7 classification290\n\n\n\n\nTumour biology: hormone receptor status, HER2 status and grade\nEstimated by tumour size, nodal involvement, metastatic status, and age of woman at tumour detection\nCanadian Cancer Registry140\n\n\n\nDisease progression\nTime to disease progression\nEstimated using Weibull regression models, adjusted to years since diagnosis, age, grade, hormone status, HER2 status, screening status, method of detection, and variable interactions\nYong et al, 2022136 Supplemental Appendix 5: Disease Progression Figure 6.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  }
]